Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 78Fluorouracil 27Oxaliplatin 24130-nm albumin-bound paclitaxel 24Leucovorin 18Capecitabine 15Albumin-Bound Paclitaxel 15S 1 (combination) 14Taxes 12Irinotecan 11pembrolizumab 9folfirinox 9Radiosurgery 9Radiotherapy 7Drug Therapy 7Cisplatin 7irinotecan sucrosofate 6Pancreaticoduodenectomy 5Paclitaxel 5Injections 5Docetaxel 5Blood Specimen Collection 5apatinib 4Radiofrequency Ablation 4Radiation 4Biopsy 4tislelizumab 3rubitecan 3nimotuzumab 3camrelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pancreatic Neoplasms × PEGPH20 × Clear all
NCT03634332 2019-05-07

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Pancreatic Cancer Research Team

Phase 2 Unknown
35 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡